A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) (CHERISH)

  • End date
    Jul 12, 2023
  • participants needed
  • sponsor
    UCB Biopharma S.P.R.L.
Updated on 12 May 2022
certolizumab pegol
interferon gamma
bacillus calmette-guerin
purified protein derivative
interferon gamma release assay


The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study participants with chronic inflammatory diseases.

Condition Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
Treatment Pharmacokinetics of certolizumab pegol
Clinical Study IdentifierNCT04163016
SponsorUCB Biopharma S.P.R.L.
Last Modified on12 May 2022


Yes No Not Sure

Inclusion Criteria

Participant is pregnant and ≤10 weeks gestation at the time of enrollment
Participant must have been on stable, maintenance dose certolizumab pegol (CZP) treatment for at least 12 weeks independent of and prior to being enrolled in this study, for an approved indication in accordance with her treating physician
Participant expects to continue CZP therapy throughout pregnancy and for at least 12 weeks postpartum
Participant has a negative interferon gamma release assay (IGRA) or tuberculin skin test (TST) within the prior 6 months, and there has been no change in the study participant's clinical status, or social, family, or travel history. Participants with documented Bacillus Calmette-Guérin (BCG) vaccine and at low risk for tuberculosis (TB) may enroll without having a TB test performed

Exclusion Criteria

Participant has any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study
Participant is not permitted to enroll into the study if she meets any of the following TB exclusion criteria
Known active TB disease
History of active TB involving any organ system
Latent TB infection
High risk of acquiring TB infection
Current nontuberculous mycobacterial (NTM) infection or history of NTM infection (unless proven to be fully recovered)
Study participant is taking a prohibited medication or has taken a prohibited
Live vaccine(s) within 1 month prior to Screening, or plans to receive such vaccines during the study
Study participant has any clinically significant pregnancy-related clinical or test abnormality, as judged by the investigator
Study participant had a positive or indeterminate interferon gamma release assay (IGRA) or tuberculin skin test (TST) at Screening. In case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the study participant
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note